Table 1.
IMPEDE VTE: A Risk Model for VTE Development in Patients with Multiple Myeloma
| Variable | Score |
| Immunomodulatory drug | +4 |
| Body Mass Index ≥25 kg/m2 | +1 |
| Pelvic, hip, or femur fracture | +4 |
| Erythropoiesis-stimulating agent | +1 |
| Doxorubicin | +3 |
| Dexamethasone Dose | |
| High-Dose | +4 |
| Low-Dose | +2 |
| Ethnicity/Race = Asian/Pacific Islander | −3 |
| History of VTE before MM | +5 |
| Tunneled line/central venous catheter | +2 |
| Existing thromboprophylaxis: therapeutic LWMH or warfarin | −4 |
| Existing thromboprophylaxis: prophylactic LWMH or warfarin | −3 |
Abbreviations: VTE, venous thromboembolism; MM, multiple myeloma; LWMH, low weight molecular heparin.